AGENDA
Mayflower Renaissance Hotel
1127 Connecticut Avenue, NW, Washington, DC

Wednesday, February 16th

6:30-8:00 pm  Opening Reception
Welcome: Debra Black, MRA Co-Founder and Chair of the Board

Thursday, February 17th

8:00-8:15  Opening Remarks: Wendy K.D. Selig, MRA President and CEO

8:15-11:25  Genetic Basis for Melanoma Prevention, Prognostics, and Therapy
Chair: David E. Fisher
8:15-8:40  Identification of novel melanoma risk genes using high-throughput genomics - Kevin Brown, National Cancer Institute
8:40-9:05  Transcriptome sequencing to detect gene fusions in melanoma - Nallasivam Palanisamy, University of Michigan
9:05-9:30  Insights from sequencing the melanoma transcriptome and exome - Ruth Halaban, Yale University
9:30-9:55  Targeting insulin receptor substrates for destruction as a therapeutic modality for treating melanoma - Alexander Levitzki, Hebrew University of Jerusalem
9:55-10:10  Break
10:10-10:35  Pro-invasion metastasis drivers in early stage melanoma are oncogenes - Lynda Chin, Dana-Farber Cancer Institute
10:35-11:00  Sulforaphane, a melanoma prevention agent for high-risk MC1R genotypes - Sancy Leachman, University of Utah
11:00-11:25  Targeted strategies for melanoma treatment and prevention - David E. Fisher, Massachusetts General Hospital

11:45-1:00  Lunch
Keynote address: Michael Milken, MRA Board Member

1:00-1:30  NIH as a Partner in Advancing Melanoma Research
Douglas R. Lowy, Deputy Director, National Cancer Institute

1:30-2:30  MRA Young Investigators
Chair: Padmanee Sharma, University of Texas MD Anderson Cancer Center
1:30-1:50  The role of oncogenic signaling pathways in human melanoma immune evasion - Patrick Ott, New York University
1:50-2:10  18F labeled benzamides for preclinical PET imaging of melanoma metastases - Zhen Cheng, Stanford University
2:10-2:30  Reactivation of p53 by small molecule inhibitors of the MDM2-p53 interaction as a strategy for the treatment of melanoma - Sanjeev Kumar Shangary, University of Michigan

2:45-5:15  Adoptive T Cell Transfer: State of the Art
Chair: Steven Rosenberg, National Cancer Institute
2:45-3:10  Manipulating immune regulation in adoptive T-cell therapy for melanoma - Laszlo Radvanyi, University of Texas MD Anderson Cancer Center
3:10-3:35 Type 17 T cells: a good choice for adoptive T-cell therapy? - Xue-Zhong Yu, Moffitt Cancer Center

3:35-4:00 Advanced immune monitoring and TCR cloning in clinical trials of T cell receptor (TCR) engineered adoptive cell transfer therapy – Antoni Ribas, University of California Los Angeles

4:00-4:25 Strategies to enhance the efficacy of adoptive T cell therapy - Cassian Yee, Fred Hutchinson Cancer Center

4:25-5:15 Tumor infiltrating lymphocytes and genetically modified T cells in the treatment of melanoma and other cancers – Steven Rosenberg, National Cancer Institute

5:15 Closing Remarks Day 1: Laura Brockway-Lunardi, MRA Scientific Program Director

---

**Friday, February 18th**

**8:00-10:35 Combinatorial Therapies for More Effective Melanoma Treatment**
Chair: Meenhard Herlyn, The Wistar Institute

8:00-8:25 A phase I trial of bevacizumab plus ipilimumab in melanoma patients - F. Stephen Hodi, Dana Farber Cancer Institute

8:25-8:50 Therapeutic inhibition of mutant activated signaling pathways in melanoma: Combinatorial therapy with immune checkpoint blockade - James Allison, Memorial Sloan-Kettering Cancer Center

8:50-9:15 Immunotherapy of melanoma with toll-enhanced vaccines and blockade of the PD-1 pathway: Toward biomarkers and combinatorial strategies – Drew Pardoll, Johns Hopkins University

9:15-9:40 Angiogenesis inhibitors and combination chemotherapies - Svetomir N. Markovic, Mayo Clinic Rochester

9:40-10:05 Identification and validation of combination therapies for melanoma - Levi Garraway, Dana-Farber Cancer Institute

**Short talks:** Combinatorial therapies to overcome resistance to BRAF(V600E) inhibition

10:05-10:20 Melanomas acquire resistance to V600E B-RAF inhibition by RTK or N-RAS upregulation - Roger Lo, University of California, Los Angeles

10:20-10:35 Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K - Meenhard Herlyn, The Wistar Institute

**10:55-11:55 Panel Discussion: Regulatory Approval Pathways for New Melanoma Therapies**
Co-chairs: Paul Chapman, Memorial Sloan-Kettering Cancer Center, and F. Stephen Hodi, Dana-Farber Cancer Institute

- Update on RO5185426 (PLX-4032) clinical results - Paul Chapman
- Update on ipilimumab clinical results - F. Stephen Hodi

Panelists:
- Jonathan Cebon, Ludwig Institute for Cancer Research, Melbourne Clinical Sciences Center
- George Demetri, Dana-Farber Cancer Institute
- Richard Pazdur, U.S. Food and Drug Administration
- Adrian Senderowicz, AstraZeneca

**11:55-12:00 Closing Remarks:** Suzanne Topalian, MRA Chief Science Officer